Abstract

Oxidative stress (OS) is increasingly recognised as a central mechanistic component of type 2 diabetes (T2D), linking chronic hyperglycaemia, insulin resistance, mitochondrial dysfunction, inflammation, and the development of vascular complications. Experimental and human data support a contributory role of reactive oxygen species in β-cell dysfunction, impaired insulin signalling, endothelial injury, and progressive tissue damage. This narrative review synthesises clinically relevant oxidative pathways and critically evaluates major biomarker classes, including lipid peroxidation products, protein and DNA oxidation markers, redox couples, antioxidant enzymes, and redox-sensitive regulatory networks. Particular emphasis is placed on analytical robustness, biological variability, methodological heterogeneity, and translational maturity. Despite extensive associative evidence, no oxidative stress biomarker currently demonstrates consistently replicated incremental prognostic value beyond established cardiometabolic risk models sufficient for routine clinical implementation. Most available data derive from cross-sectional or intermediate translational studies, with limited prospective outcome validation. Although glucose-lowering therapies and lifestyle interventions may reduce oxidative biomarker levels, modulation of these markers has not been established as a validated mediator of clinical benefit. At present, oxidative biomarkers remain primarily mechanistic and research tools, and meaningful clinical integration will require assay harmonisation and rigorous longitudinal demonstration of added predictive or therapeutic value.